PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21959602-9 2011 Treatment with rosiglitazone improved survival rate, decreased the markers of organ injury, and suppressed the release of TNF-alpha, IL-6, and MCP-1 after HS in rats. Rosiglitazone 15-28 interleukin 6 Rattus norvegicus 133-137 22219595-13 2011 Additionally, rosiglitazone significantly reduced the concentration of TNF-alpha, IL-1beta, IL-6 and ALT in sham-operated rats, but not in BDL rats, in response to LPS (3 mg/kg). Rosiglitazone 14-27 interleukin 6 Rattus norvegicus 92-96 21959602-10 2011 CONCLUSIONS: Treatment with rosiglitazone suppresses the release of serum TNF-alpha, IL-6 and MCP-1, and ameliorates HS-induced organ damage in rats. Rosiglitazone 28-41 interleukin 6 Rattus norvegicus 85-89 21893696-11 2011 The activated PPAR-gamma inhibit the expression of proinflammatory factors, such as IL-6, TNF-alpha, and neutrophil chemotaxis, which was evidenced by MPO reduction in serum and colon homogenates mediated by rosiglitazone. Rosiglitazone 208-221 interleukin 6 Rattus norvegicus 84-88 21455100-10 2011 Rosiglitazone alone decreased expression of IL-6; used with TNBS it decreased expression of MPO in intestinal tissue, yet did not increase the expression of IL-10. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 44-48 21455100-15 2011 Rosiglitazone inhibits expression of proinflammatory IL-6 and does not affect IL-10. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 53-57 20034949-9 2011 Rosiglitazone diminished the increase in HR, decreased the markers of organ injury (GOT, GPT, BUN, Cre, LDH, CPK, glucose) and inflammatory biomarkers (TNF-alpha, IL-6), and did not affect MAP after LPS. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 163-167 20034949-10 2011 In conclusion, rosiglitazone ameliorated endotoxin shock-induced markers of organ injury and suppressed the release of TNF-alpha and IL-6 in conscious rats. Rosiglitazone 15-28 interleukin 6 Rattus norvegicus 133-137 19143945-9 2009 Rosiglitazone significantly decreased apoptosis, TGF-beta, IL-6, alpha-SMA expression and NO availability in obstructed kidneys. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 59-63 21224499-14 2010 Rosiglitazone decreased the expression of inflammatory cytokines, such as IL-6 and TNF-alpha, both in serum and in intestinal homogenates. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 74-78 21224499-16 2010 Rosiglitazone reduces inflammation by decreasing the expression of IL-6 and TNF-alpha. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 67-71 17975301-9 2008 Rosiglitazone treatment abrogated augmented IL-6, A-II and TGF-beta synthesis and restored intrarenal NO availability in the remaining kidneys. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 44-48 17975301-11 2008 CONCLUSIONS: Rosiglitazone treatment attenuates the proinflammatory responses, represented by augmented IL-6, A-II and TGF-beta production, developing in the remaining kidney following contralateral nephrectomy. Rosiglitazone 13-26 interleukin 6 Rattus norvegicus 104-108 31015796-5 2019 In in vitro neurons, G3335 (PPAR-gamma antagonist) reversed the rosiglitazone-induced inhibition of caspase-1, interleukin 1 (IL-1beta), and interleukin 6 (IL-6). Rosiglitazone 64-77 interleukin 6 Rattus norvegicus 141-154 17436085-6 2007 Rosiglitazone improved inflammation in NASH and improved ALT, alkaline phosphatase, and interleukin-6 levels in the induction study and interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha levels in the treatment study. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 88-101 17436085-6 2007 Rosiglitazone improved inflammation in NASH and improved ALT, alkaline phosphatase, and interleukin-6 levels in the induction study and interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha levels in the treatment study. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 155-201 17394460-8 2007 Rosiglitazone treatment curtailed the post-ischemic expression of the pro-inflammatory genes interleukin-1beta, interleukin-6, macrophage inflammatory protein-1alpha, monocyte chemoattractant protein-1, cyclooxygenase-2, inducible nitric oxide synthase, early growth response-1, CCAAT/enhancer binding protein-beta and nuclear factor-kappa B, and increased the expression of the anti-oxidant enzymes catalase and copper/zinc-superoxide dismutase. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 112-125 17641846-7 2007 RSG (0.5 and 2 mg/kg) could decrease the expression levels of IL-6 mRNA in brain tissue after MCA occlusion and reperfusion to varying degrees (P<0.05) with the difference being significant between them. Rosiglitazone 0-3 interleukin 6 Rattus norvegicus 62-66 15665514-0 2005 The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes. Rosiglitazone 23-36 interleukin 6 Rattus norvegicus 152-156 15665514-9 2005 Treatment of neonatal rat ventricular myocytes with 10 micromol/L rosiglitazone enhanced TNF-alpha- and lipopolysaccharide-induced NF-kappaB-dependent transcription by approximately 1.8- and approximately 1.4-fold respectively, and TNF-alpha-induced IL-6 secretion by n1.5-fold. Rosiglitazone 66-79 interleukin 6 Rattus norvegicus 250-254 31493866-6 2019 The in vitro experiments showed that rosiglitazone treatment repressed the expression of TNFalpha and IL-6 induced by antigen-challenged RBL-2H3 cells in a peroxisome proliferator-activated receptor gamma (PPARgamma)-independent manner, which was related to the repression of protein kinase C (PKC)-beta1 activation. Rosiglitazone 37-50 interleukin 6 Rattus norvegicus 102-106 31015796-5 2019 In in vitro neurons, G3335 (PPAR-gamma antagonist) reversed the rosiglitazone-induced inhibition of caspase-1, interleukin 1 (IL-1beta), and interleukin 6 (IL-6). Rosiglitazone 64-77 interleukin 6 Rattus norvegicus 156-160 31015796-6 2019 Rosiglitazone inhibited the expression of NLRP3, caspase-1, IL-1beta, and IL-6. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 74-78 29290188-8 2018 Rosiglitazone treatment from days 14 to 20 ameliorated hypertension, improved renal function, decreased endothelin-1 (ET-1), angiotensin II (Ag II) and interleukin (IL-6), while it increases NO level and pup weight. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 165-169 28259952-8 2017 The RPMCs were damaged by stimulation with 4.25% PDS for 72 h. The expression levels of AQP-1 and ZO-1 were increased, and the secretion of IL-6 and IL-8 were decreased by rosiglitazone. Rosiglitazone 172-185 interleukin 6 Rattus norvegicus 140-144 26394869-7 2016 Western blot analysis showed that rosiglitazone significantly decreased protein expression levels of COX-2 and production of pro-inflammatory markers, including TNF-alpha and IL-6, in D-GaIN/LPS-treated rat liver. Rosiglitazone 34-47 interleukin 6 Rattus norvegicus 175-179 26047949-13 2015 Rosiglitazone pretreatment significantly decreased ICAM-1 mRNA upregulation, secretion of IL-6 protein, and phosphorylation of NF-kappaB-p65 and IkappaBalpha without decreasing CD40 mRNA expression. Rosiglitazone 0-13 interleukin 6 Rattus norvegicus 90-94 24839089-5 2014 The results showed that rosiglitazone attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), and the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner. Rosiglitazone 24-37 interleukin 6 Rattus norvegicus 191-204 24839089-5 2014 The results showed that rosiglitazone attenuated the infiltration of inflammatory cells, the activity of myeloperoxidase (MPO), and the production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1beta (IL-1beta) in a dose-dependent manner. Rosiglitazone 24-37 interleukin 6 Rattus norvegicus 206-210